3 Reasons Rocket Lab Stock Could Double in 2027 -- and 1 Reason It Might Not

The key underwriting issue is conversion, not demand: backlog and pre-flight commitments do not establish revenue timing, contract economics, or cash returns. Verify funded backlog, milestone schedules, cancellation terms, and segment margins before treating defense awards as a durable earnings floor. Vertical integration may reduce supplier dependence, but it also puts more manufacturing yield, capacity, and working-capital risk on Rocket Lab itself.

Near term, the stock is exposed to schedule language and launch milestones; a pad-delivery target is not equivalent to a first-flight date. Over 1–3 months, any clarification of Neutron test cadence and contract timing could reset expectations. Over 6–18 months, a successful flight would improve credibility for larger national-security missions, while a delay or failure could push opportunities toward established providers such as SpaceX, ULA, and Blue Origin. A successful first flight alone would not prove reliable cadence or attractive economics.

Contrarian point: the existing business may limit downside only if its cash generation can support Neutron development; revenue growth and backlog alone do not prove that cushion. Without valuation, cash-flow, and program-cost data, the article’s implied upside is not a basis for sizing a long position.